Tony Berberabe, MPH | Authors


Safety, Pharmacokinetic Findings Are Revealed for MET Inhibitor TPX-0022

December 01, 2020

The MET inhibitor TPX-0022 was safe and well tolerated in a phase 1 dose-escalation study, SHIELD-1, involving patients with advanced solid tumors harboring MET alterations, according to results presented during the 32nd Molecular Targets and Cancer Therapeutics Symposium.

Palbociclib Demonstrates Prolonged OS/PFS When Initiated in Metastatic Breast Cancer

November 15, 2020

Patients who received palbociclib and fulvestrant before chemotherapy for metastatic breast cancer had greater clinical benefit versus patients who received placebo and fulvestrant, according to an exploratory subgroup analysis of the phase 3 PALOMA-3 trial.

Safety, Tolerability Profile for Low-Dose Lenvatinib Is Similar to Standard Dose in RCC

November 07, 2020

Findings from a phase 2 trial evaluating lenvatinib given at 2 different starting doses, 14 mg versus 18 mg, in combination with everolimus, suggest the lower dose is similar to the standard dose in terms of efficacy and safety with minimal differences observed between the 2 arms.

Across Cancer Settings, ICIs Continue to Make Deep Inroads

October 27, 2020

With immune checkpoint inhibitors gaining widespread adoption, their optimal use hinges on a greater understanding of biomarkers, practical applications, and their potential in combination with cellular therapies.